Evanthia Galanis, MD
Alliance Foundation Trials, LLC.
7
7
1
N/A
0
7
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Yvonne A. Efebera, MD
Ohio State University Comprehensive Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Jacob P. Laubach, MD
Dana-Farber Cancer Institute
Shared therapeutic areas:
Worked with same sponsors:
David Kozono, MD
Alliance Foundation Trials, LLC.
Shared therapeutic areas:
Worked with same sponsors:
James Urbanic, MD
University of California, San Diego
Shared therapeutic areas:
Worked with same sponsors:
Linda Martin, MD, MPH
University of Virginia
Shared therapeutic areas:
Worked with same sponsors:
Michael Gnant, MD
ABCSG, Medical University Vienna
Shared therapeutic areas:
Worked with same sponsors:
Erica Mayer, MD
Dana-Farber Cancer Institute
Shared therapeutic areas:
Worked with same sponsors:
Helen Ross, MD
Rush University
Shared therapeutic areas:
Worked with same sponsors:
Chi-Fu Jeffrey Yang, MD
Massachusetts General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jacob Sands, MD
Dana-Farber Cancer Institute
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
All 7 trials loaded